Bio Blast Pharma Ltd. (ORPN) Rating Increased to Buy at Zacks Investment Research

Zacks Investment Research upgraded shares of Bio Blast Pharma Ltd. (NASDAQ:ORPN) from a hold rating to a buy rating in a report released on Tuesday morning. The brokerage currently has $2.00 price target on the biopharmaceutical company’s stock.

According to Zacks, “Bio Blast Pharma Ltd. is a clinical-stage biotechnology company. It engages in developing therapies for patients with rare and ultra-rare genetic diseases. Bio Blast products include Cabaletta to treat oculopharyngeal muscular dystrophy, Machado Joseph disease or SCA3, and Kennedy’s disease or SBMA; BBrm to treat diseases caused by nonsense mutation; and mPRT to treat mitochondrial protein deficiency diseases. The Company offers its products to the healthcare and medical industries. Bio Blast Pharma Ltd. is headquartered in Tel Aviv, Israel. “

A number of other brokerages also recently weighed in on ORPN. Roth Capital restated a buy rating and set a $15.00 price objective (down previously from $23.00) on shares of Bio Blast Pharma in a research report on Monday, June 13th. Rodman & Renshaw restated a buy rating on shares of Bio Blast Pharma in a research report on Monday, July 11th. Five analysts have rated the stock with a buy rating, Bio Blast Pharma has a consensus rating of Buy and a consensus target price of $19.40.

Bio Blast Pharma (NASDAQ:ORPN) opened at 1.71 on Tuesday. The company’s market cap is $28.03 million. The stock’s 50 day moving average is $1.70 and its 200-day moving average is $2.04. Bio Blast Pharma has a 52-week low of $1.50 and a 52-week high of $7.95.

Bio Blast Pharma (NASDAQ:ORPN) last issued its earnings results on Thursday, August 25th. The biopharmaceutical company reported ($0.22) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.27) by $0.05. During the same quarter in the prior year, the company posted ($0.26) earnings per share. Equities research analysts predict that Bio Blast Pharma will post ($1.03) EPS for the current fiscal year.

A hedge fund recently bought a new stake in Bio Blast Pharma stock. Sabby Management LLC bought a new position in shares of Bio Blast Pharma Ltd. (NASDAQ:ORPN) during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 1,133,937 shares of the biopharmaceutical company’s stock, valued at approximately $2,824,000. Sabby Management LLC owned approximately 7.97% of Bio Blast Pharma as of its most recent SEC filing. 7.82% of the stock is currently owned by institutional investors.

About Bio Blast Pharma

Bio Blast Pharma Ltd. (BioBlast) is a development-stage biopharmaceutical company. The Company is focused on the identification, licensing, acquisition, development and commercialization of drugs for rare and ultra-rare genetic and metabolic diseases. It focuses on therapeutic platforms that offer solutions for several diseases that share a common pathophysiological mechanism, which are the functional changes that accompany a particular syndrome or disease.

5 Day Chart for NASDAQ:ORPN

Get a free copy of the Zacks research report on Bio Blast Pharma (ORPN)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Bio Blast Pharma Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio Blast Pharma Ltd. and related companies with's FREE daily email newsletter.

Leave a Reply

© 2006-2016 Mideast Time.